<DOC>
	<DOC>NCT01744691</DOC>
	<brief_summary>An Open-label, Single arm, Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor ibrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma with 17p Deletion</brief_summary>
	<brief_title>A Multicenter Phase 2 Study of Ibrutinib in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) With 17p Deletion</brief_title>
	<detailed_description>This is a multicenter, international, open-label, single arm, Phase 2 study designed to evaluate the efficacy and safety of ibrutinib in subjects with relapsed/refractory CLL or SLL with del 17p. All subjects will receive ibrutinib until disease progression or unacceptable toxicity occurs.</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
	<criteria>Key Documentation of del (17p13.1) Must have relapsed or refractory CLL/SLL after receiving at least 1 prior line of systemic therapy. Measurable nodal disease by computed tomography (CT) Key History or current evidence of Richter's transformation or prolymphocytic leukemia Prior hematologic stem cell transplantation &lt;6 months from study enrollment or any ongoing GVHD Prior exposure to ibrutinib</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>CLL</keyword>
	<keyword>SLL</keyword>
</DOC>